The invention relates to recombinant adenovirus displaying one or more heterologous epitope(s) on their fiber protein. These recombinant adenovirus are useful as vaccines for generating an immune response against said epitope(s) in individuals having a pre-existing anti-Ad immunity.

A recombinant vector comprises simian adenovirus sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.

An immunization regimen is provided which involves priming with an E1, E4-deleted adenovirus and boosting with an E1-deleted adenovirus. The second administered adenovirus has a capsid of a serotype which is not cross-reactive with the previously administered adenovirus. Further, a product containing the adenoviruses necessary to perform the immunization regimen is provided.

An immunotherapeutic composition is contemplated that comprises subject-derived peripheral blood mononuclear cells (PBMC) and at least one recombinant adenovirus subtype 5 (Ad5) comprising a deletion in an E1 gene region, a deletion in an E2b gene region, and a nucleic acid sequence encoding a peptide antigen, wherein the PBMC are exposed ex-vivo to the at least one Ad5 vector. Advantageously, the same PBMC composition may also be used to prepare modified NK cells, and especially modified NK include CIML NK cells, CENK cells and mCENK cells.

An immunotherapeutic composition is contemplated that comprises subject-derived peripheral blood mononuclear cells (PBMC) and at least one recombinant adenovirus subtype 5 (Ad5) comprising a deletion in an E1 gene region, a deletion in an E2b gene region, and a nucleic acid sequence encoding a peptide antigen, wherein the PBMC are exposed ex-vivo to the at least one Ad5 vector. Advantageously, the same PBMC composition may also be used to prepare modified NK cells, and especially modified NK include CIML NK cells, CENK cells and mCENK cells.

The invention relates to a recombinant adenovirus nucleic acid wherein the gene encoding protein V and/or the gene encoding protein VII is placed under control of a heterologous promoter, to a recombinant adenovirus nucleic acid wherein the adenoviral nucleotide sequence is mutated in such a way that it is no longer capable of producing one or more of the coat proteins, to cellular vesicles filled with such adenoviral material, cells provided with such adenoviral material and to methods and use thereof.

The present disclosure provides a respiratory syncytial virus-based adenovirus vector vaccine, a method for preparing same, and use thereof. Specifically, an adenovirus vector suitable for a transmucosal formulation against RSV is selected from a variety of adenovirus vectors. The vaccine is administered by inhalation, which can simulate the virus infection process, stimulate the immune response, and avoid local adverse effects such as injection site pain and the like due to intramuscular injection. By means of inhalation, the atomized vaccine can finally reach the lung through the respiratory tract, thus inducing the respiratory tract mucosal immunity while stimulating the humoral immunity and cellular immunity. The stimulation of the pulmonary mucosal immunity is the most effective method for preventing RSV infection and spread. The vaccine stimulates the lung mucosal immunity and exhibits a well induced humoral immunity level. The present disclosure screens the dose for inhalation and the selected dose is lower compared with the that of the intramuscular injection, thus possessing better safety.

The present disclosure describes methods, compositions, and kits related to the combination of a TLR7 modulating compound and an HIV vaccine. The combination can be used in a method of treating or preventing an HIV infection in a human.